Remopharma
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €3.0m. Estimated: probably between €2.2m and €4.1m.
Balance sheet
balance sheet total €3.7m on 31-12-2025in €m
in euro
Position in the sector
60.2%
Higher than 74% of 13,289 companies in 2025.
1.83
Higher than 59% of 13,148 companies in 2025.
6.6%
Higher than 60% of 13,209 companies in 2025.
Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: top quarter · Staff: middle half
Staff
€65,124
Staff costs divided by the average number of full-time equivalents.
level
In 2025, 2 employees joined and 2 left.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 200916 months |
|---|---|---|---|---|---|
| Balance sheet: assets | |||||
20/58 |
3.7m | 3.3m | 3.3m | 767,116 | |
21/28 |
2.1m | 1.8m | 1.9m | 488,715 | |
21 |
122,779 | 148,179 | 173,579 | 208,000 | |
22/27 |
2.0m | 1.7m | 1.7m | 280,715 | |
22 |
1.2m | 1.1m | 1.2m | 196,296 | |
23 |
843,549 | 553,225 | 488,769 | 477 | |
24 |
16,562 | 18,252 | 11,380 | 83,942 | |
29/58 |
1.5m | 1.5m | 1.4m | 278,401 | |
3 |
507,696 | 497,991 | 464,978 | 82,009 | |
30/36 |
507,696 | 497,991 | 464,978 | 82,009 | |
40/41 |
333,208 | 255,574 | 277,146 | 42,275 | |
40 |
300,944 | 220,225 | 235,708 | 39,468 | |
41 |
32,264 | 35,350 | 41,438 | 2,806 | |
50/53 |
426,222 | 501,222 | 376,222 | - | |
54/58 |
233,124 | 194,009 | 252,574 | 152,593 | |
490/1 |
17,718 | 14,745 | 13,487 | 1,525 | |
| Balance sheet: equity and liabilities | |||||
10/49 |
3.7m | 3.3m | 3.3m | 767,116 | |
10/15 |
2.2m | 2.0m | 1.7m | 137,968 | |
10/11 |
1,000 | 1,000 | 1,000 | 116,000 | |
100 |
- | - | - | 116,000 | |
13 |
2.2m | 2.0m | 1.7m | 21,968 | |
130/1 |
- | - | 0 | - | |
130 |
- | - | - | 11,600 | |
1311 |
- | - | 0 | - | |
132 |
118 | 118 | 118 | - | |
133 |
2.2m | 2.0m | 1.7m | 10,368 | |
17/49 |
1.5m | 1.3m | 1.6m | 629,148 | |
17 |
629,311 | 716,145 | 831,724 | 440,646 | |
170/4 |
629,311 | 716,145 | 831,724 | 440,646 | |
42/48 |
827,712 | 629,551 | 747,208 | 187,657 | |
42 |
124,793 | 132,755 | 149,913 | 36,080 | |
44 |
628,904 | 447,431 | 499,077 | 77,346 | |
440/4 |
628,904 | 447,431 | 499,077 | 77,346 | |
45 |
73,891 | 49,280 | 98,063 | 6,040 | |
450/3 |
18,138 | 11,003 | 61,105 | 6,040 | |
454/9 |
55,753 | 38,277 | 36,958 | - | |
47/48 |
125 | 85 | 155 | 68,191 | |
492/3 |
1,250 | 1,832 | 3,452 | 845 | |
| Income statement | |||||
9900 |
1.1m | 965,347 | 932,226 | 161,901 | |
62 |
455,871 | 329,855 | 303,705 | - | |
630 |
205,996 | 179,294 | 160,548 | 78,773 | |
640/8 |
24,011 | 14,266 | 11,974 | 30,363 | |
9901 |
416,371 | 441,932 | 455,999 | 52,766 | |
75/76B |
11,596 | 14,555 | 6,441 | 31 | |
75 |
11,596 | 14,555 | 6,441 | 31 | |
65/66B |
112,541 | 61,768 | 61,166 | 24,783 | |
65 |
112,541 | 61,768 | 61,166 | 24,783 | |
9903 |
315,427 | 394,719 | 401,274 | 28,013 | |
67/77 |
74,285 | 99,124 | 97,154 | 6,045 | |
9904 |
241,142 | 295,595 | 304,120 | 21,968 | |
9905 |
241,142 | 295,595 | 304,120 | 21,968 | |
| Appropriation of the result | |||||
9906 |
241,142 | 295,595 | 304,120 | 21,968 | |
691/2 |
241,142 | 295,595 | 304,120 | 21,968 | |
6920 |
- | - | - | 11,600 | |
6921 |
241,142 | 295,595 | 304,120 | 10,368 | |
| Social balance sheet | |||||
9087 |
7 | 6.1 | 5.3 | - | |
Hours worked1013 |
12,209 | 9,528 | 9,221 | - | |
| Document | |||||
The notes to these accounts have 24 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 18-08-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank2025 annual accounts filed 18 days after the deadline. Filed on 18 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00403475.
Subsidies and aid
Flemish government 2024 to 2025, 2 entries, €3,340 awarded, €3,340 paid
| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 1 | €2,531 | €2,531 |
| 2024 | 1 | €809 | €809 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 200916 months |
|---|---|---|---|---|---|
| 622,368 | 621,226 | 616,547 | 131,539 | ||
| 447,138 | 474,889 | 464,668 | 100,741 | ||
| 503,456 | 160,898 | 157,581 | 567,488 | ||
| 39,114 | -58,564 | - | - | ||
| 690,255 | 833,990 | 637,198 | 90,744 | ||
| 60.2% | 59.3% | 51.3% | 18.0% | ||
| 1.83 | 2.32 | 1.85 | 1.48 | ||
| 1.22 | 1.53 | 1.23 | 1.05 | ||
| 0.66 | 0.69 | 0.95 | 4.56 | ||
| 10.9% | 15.1% | 18.2% | 15.9% | ||
| 6.6% | 8.9% | 9.4% | 2.9% | ||
| 5.53 | 10.06 | 10.08 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 |
|---|---|---|---|
| Employees at the balance-sheet date | 9 | 9 | 7 |
| full-time | 4 | 4 | 3 |
| part-time | 5 | 5 | 4 |
| in full-time equivalents | 7 | 6.8 | 5.8 |
| 7 | 6.1 | 5.3 | |
| On a permanent contract | 8 | 8 | 6 |
| Joined | 2 | 6 | 4 |
| Left | 2 | 4 | 4 |
Source: social balance sheet in the 2023 to 2025 annual accounts
Securities and guarantees
on own assets and for others| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Debts guaranteed by Belgian public bodies | €754,104 | - | - |
Source: notes to the 2023 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Tangible fixed assets | €503,456 | €160,898 | €157,581 |
| Financial fixed assets | €0 | - | - |
| €205,996 | €179,294 | €160,548 |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on Remopharma
The operating result for 2025 is 6% lower than in 2024 and the lowest since 2009. It is the second fall in a row.
Debt's share of the balance-sheet total falls from 40.7% to 39.8%. Equity and debt are higher.